Openbookopenbook
Equity
ZYME
+0.0 · +0.00%
USD · NASDAQ

Zymeworks Inc. Common Stock(ZYME) Stock Analysis | Healthcare

USD --+0.00%
Reward35Moderate
Risk44Moderate
75%Data
Revenue down 91% YoY
Value Trap
Market Cap:2.02Bn
ⓘ
Reward Rating
35
Moderate
Reward Assessment
75% data coverage
Bottom 5% of stocksView factors
ⓘ
Risk Rating
44
Moderate
Risk Assessment
5 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ZYME to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for ZYME, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $41.58.

What is Zymeworks Inc. Common Stock?

, a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases.

ZYME · Verdict

Limited reward · moderate risk

ZYME stands out on balance sheet and valuation, but watch the cash flow signal.

Based on 88% data coverage

ZYME · Verdict

What’s working & what to watch

Strengths 2

  • Balance sheet86/100

    Current ratio 5.52

  • Valuation71/100

    P/E 19.2×

Watchouts 3

  • Cash flow6/100

    -33% free-cash-flow margin

  • Growth13/100

    Revenue -36.4% CAGR

  • Profitability32/100

    -77% net margin · -72% ROE

Model-based scoring. For information only — not financial advice.

What is Zymeworks Inc. Common Stock?

, a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 2.02B.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (35)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

MESOMid Cap / 2B market cap
Mesoblast Ltd
Compare
STOKMid Cap / 2B market cap
Stoke Therapeutics Inc
Compare
GENBMid Cap / 2.1B market cap
Generate Biomedicines, Inc. Common Stock
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap2.02B
P/E RatioN/A
Dividend YieldN/A
Beta1.149
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
8187,933 shares
$4.7M
0
9-12months
0
0
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.